SwitzerlandSwitzerland

Novartis pays $125m in cash for better access to fast-growing Chinese vaccine market

06.11.2009

Basel –Novartis AG has begun to fulfill its announced investment of $1.25bn to boost the company’s limited presence in the fast-growing Chinese health market over the next 5 years. The swiss drug makers will acquire a 85% stake in Chinese vaccine specialist Zhejiang Tianyuan Bio-Pharmaceutical Co. for $125m in cash. The privately-held enterprise had net sales of $25m last year with vaccines against seasonal influenza, hemorrhagic fever with renal syndrome, Japanese encephalitis, and meningococcal meningitis. Novartis said the deal will facilitate the introduction of its own vaccines against rabies and influenza in China. The purchase, subject to government and regulatory approval in China, is expected to be finalised at the beginning of next year.
China is the world's third largest vaccines market, with annual industry sales of more than $1bn and expectations of sustained double-digit growth in the future.
The news of the deal came on the heels of Novartis’ announced investment of $1.25bn in China-based R&D activities. The company will also put $250m into the expansion of the Novartis Institute for BioMedical Research, to be relocated to a new campus in Shanghai, as well as $250m in a new global technical center opening in Changshu, to be focused on technical research, development, and API manufacturing.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/novartis-pays-125m-in-cash-for-better-access-to-fast-growing-chinese-vaccine-market.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014


Current issue

All issues

Product of the week

Products